Cartesian begins trial of RNA-based cell therapy for COVID-19
Cartesian Therapeutics has initiated a phase I/II clinical trial for the use of its Descartes-30 lead RNA-engineered mesenchymal stem cell therapy in patients with moderate-to-severe acute respiratory distress syndrome (ARDS), including ARDS caused by COVID-19.
Molecular barcoding of DNA identifies rare mutations in stem cells
Scientists have developed a new next-generation sequencing technique using molecular barcodes that can accurately detect a single genetic mutation in a pool of 10,000 cells. The researchers applied the approach to CRISPR-Cas9 genome editing to search for undesirable mutations caused by the platform. The research and methods were published in Genome Biology on August 24.  Discuss
Carisma, NYU Langone to develop Vpx lentiviral vector
Carisma Therapeutics has entered into a scientific research and licensing agreement with NYU Langone Health to attain exclusive rights to develop and commercialize a Vpx lentiviral vector globally for all indications.
Expression Therapeutics develops stem cell lentiviral gene therapy
Expression Therapeutics has developed a potentially curative gene therapy candidate for familial hemophagocytic lymphohistiocytosis type 3.
IsoPlexis, Lonza partner on cell therapy manufacturing
IsoPlexis and Lonza have partnered to advance automated cell therapy manufacturing.
Fujifilm Diosynth breaks ground on biologics facility
Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization for biologics, viral vaccines, and gene therapies, held a virtual groundbreaking ceremony on August 19 for its Advanced Therapies Innovation Center construction project in Texas.
Companies work to develop combo mAb, NK cell COVID-19 therapy
A new research project is bringing together universities and pharmaceutical companies to collaborate on the development of a combination of a monoclonal antibody (mAb) and natural killer (NK) cells as a treatment for COVID-19. The efforts are spearheaded by Harbour BioMed and expand on the company's work in using mAb against SARS-CoV-2.
Carma Cell Therapies expands phase I trial of cell therapy
Carma Cell Therapies said it has expanded the phase I trial of its Mcy-M11 lead anti-mesothelin messenger RNA chimeric antigen receptor- peripheral blood mononuclear cell cell-therapy candidate to include a new parallel cohort of patients and two additional clinical sites.
Intravacc RSV vaccine candidate posts phase I trial results
Intravacc released results of a clinical phase I trial evaluating its live attenuated respiratory syncytial virus (RSV) vaccine candidate.
Genetic engineering shows how 'foreign' DNA impacts evolution
A new study has demonstrated that "foreign" DNA -- DNA transferred horizontally into a species from a source other than a parent -- can become functional over time and can impact an organism's evolution and fitness, according to a paper published August 10 in Nature Ecology and Evolution.  Discuss
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter